From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
about
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceChallenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsMulti-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersRecent Insights into the HIV/AIDS Pandemic.Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled StudyFitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latencyHIV life cycle, innate immunity and autophagy in the central nervous systemDamaging the Integrated HIV Proviral DNA with TALENs.Incorporating alternative splicing and mRNA editing into the genetic analysis of complex traits.Genome editing strategies: potential tools for eradicating HIV-1/AIDS.Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).The mTOR Complex Controls HIV Latency.Multiple UBXN family members inhibit retrovirus and lentivirus production and canonical NFκΒ signaling by stabilizing IκBα.FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral LatencyHIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDSDefining HIV and SIV Reservoirs in Lymphoid Tissues.Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads.Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.Current views on HIV-1 latency, persistence, and cure.Bispecific antibodies for viral immunotherapy.Underlying mechanisms of HIV-1 latency.Barriers to HIV remission research in low- and middle-income countries.Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads.Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.Navigating the Host Cell Response during Entry into Sites of Latent Cytomegalovirus Infection.
P2860
Q21090483-69538134-94EA-43E6-88A4-A1DB18885092Q26781511-40887F02-D02E-4D9D-B2D6-151D617E42E3Q27312050-E5316C0C-7A8D-4230-9155-5E6231CCBCB6Q30235024-BE6D47AF-D4C6-4774-9D51-238DD655B199Q33843685-348D0395-7530-426E-B198-1B4F0997AC82Q34303589-AE3453C7-1307-4A79-867B-E3D8FFA730E8Q34420382-07228B4C-4FFA-4A47-B2F6-8AEFD3D8D015Q34475249-E5EA3CA1-3069-445D-BAFD-74D1A7E03E24Q34789256-954209F7-F357-4C7E-8849-42BF49D4F11FQ35612053-3CFCB0CE-3DCA-4766-86DF-7B0C4FA65E8EQ35637027-640518E7-3BE1-4AFA-A642-6965152182F9Q35652578-E145E0A7-F3F2-4759-9B82-3B0356E34EE4Q36080407-C9DC79C9-3289-4116-A4A2-49FB35C22C93Q36225471-3E0B82F7-7DA2-44B1-882D-B393BA7E636BQ36267881-24E39DEB-DEE6-4ED6-815F-BC043ADF992AQ36283854-9299EC05-F957-411C-84FF-AEBBF3EDFE91Q36428308-00482AB3-A7AB-4592-86AE-7CD3AFF0BF00Q36613666-CF8CC928-CD2C-468D-BE97-DC5DFC9FF022Q37090999-6C3B2507-2DBB-4142-BD54-07B929AB51FAQ37281138-7A27B765-E248-499A-BC27-A51D374AFAA0Q37300347-953DC995-103E-47FD-ABB7-EA88735B22C5Q37383798-964323A6-AA43-4F8D-AE72-8D9AABF7DD7CQ37425205-CA939BB5-2796-4D3F-A97D-BC7B930EF20CQ38201765-4BAFAC82-BB11-49AA-8041-7B968566AA46Q38204866-668E8EE2-A838-4668-A321-6CD7B03ABB3BQ38718627-1763030B-1129-42FA-AAE5-8D86D95BDFABQ38973362-B92E451C-1351-40D7-B23B-BF656F31CF79Q38992408-F53B162C-E230-4C98-B61A-2426B1F4762FQ39160623-251FB9C3-C3C0-4C51-83AD-67199B8A3AA0Q39366791-34C6B4C6-E247-476C-816A-41DA158FE4ADQ39404652-8EBB005F-4729-4608-B41F-71C404185CA0Q40232001-22E117B0-018C-4819-BA39-82DEA933D2A2Q40401650-12589983-99F5-4DE2-95F6-55F5DC6D8322Q40752303-ADB59412-147F-4D62-AAB5-9B782650B245Q42196466-0F1196AE-A60A-4415-BA50-1504C4F1AAE2Q43564279-71B9D7DF-A0C3-42B3-A49B-FC764CA63CA2Q47564917-EBDC4A54-36DE-4DA8-B818-284902871829Q54254744-5C500BCF-69A8-48E2-9789-252DAB31DA93
P2860
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
From reactivation of latent HI ...... barriers to viral eradication.
@en
type
label
From reactivation of latent HI ...... barriers to viral eradication.
@en
prefLabel
From reactivation of latent HI ...... barriers to viral eradication.
@en
P2860
P356
P1433
P1476
From reactivation of latent HI ...... barriers to viral eradication.
@en
P2093
Liang Shan
P2860
P304
P356
10.1002/BIES.201200170
P407
P577
2013-04-24T00:00:00Z